Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2020 Nov 17;15(1):53–60. doi: 10.5009/gnl20247

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © Gut and Liver.

This is an open-access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

PMC Copyright notice

Fig. 1 — Effect of tegoprazan and vonoprazan on the antibiotic susceptibility of Helicobacter pylori. (A) Effect of improving susceptibility acquired by the addition of tegoprazan. Clarithromycin (46.3%), fluoroquinolone (46.7%), metronidazole (55.6%), and amoxicillin (34.5%) increased the minimum inhibitory concentration (MIC) by more than 1-fold relative to that of tegoprazan. The highest overall improvement rate in the MIC was 55.6%, and the acquired susceptibility rate of metronidazole was 20.6%. (B) Effect of improving susceptibility acquired by the addition of vonoprazan. Clarithromycin (42.6%), fluoroquinolone (33.3%), metronidazole (52.4%), and amoxicillin (31.0%) improved the MIC. Clarithromycin (5.6%), fluoroquinolone (6.7%), and metronidazole (4.7%) acquired susceptibility.